Infliximab for Paradoxical Reactions in Pediatric Central Nervous System Tuberculosis
Yara‐Natalie Abo, Nigel Curtis, Joshua Osowicki, Gabrielle M. Haeusler, Rachael Purcell, Seilesh Kadambari, Matthias De Wachter, Koen Vanden Driessche, Sven Dekeyzer, Lee Coleman, Nigel W. Crawford, Steve Graham, Ben J. Marais, Amanda Gwee
Abstract
Paradoxical reactions in central nervous system tuberculosis (CNS-TB) are associated with significant morbidity and mortality. We describe 4 HIV-uninfected children treated for CNS-TB with severe paradoxical reactions unresponsive to corticosteroids. All made recovery after treatment with infliximab, highlighting the safety and effectiveness of infliximab for this complication, and need for prospective trials.
Topics & Concepts
MedicineInfliximabParadoxical reactionCentral nervous systemTuberculosisComplicationHuman immunodeficiency virus (HIV)PediatricsIntensive care medicineImmunologySurgeryInternal medicinePathologyTumor necrosis factor alphaInfectious Diseases and TuberculosisTuberculosis Research and EpidemiologyMycobacterium research and diagnosis